NICE does not recommend Jakavi (Novartis) for Myelofibrosis
NICE (National Institute for Health and Clinical Excellence) in its draft guidance stated that it is not recommending Jakavi (ruxolitinib) from Novartis, for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adults with primary Myelofibrosis, or Myelofibrosis secondary to polycythaemia vera or essential Thrombocythaemia.
NICE stated that although the drug might offer a survival benefit, it found uncertainties in the data used by Novartis to estimate the degree of survival benefit. The Committee also said that there were fundamental issues with the costing model, making its cost-effectiveness uncertain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.